Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
TuHURA Biosciences, Inc. (HURA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.61-6.40%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HURA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain $50 million revolving credit facility funding operations | TuHURA has a $50 million credit line to fund work until 2028. | Intact | credit facility falls below $50 million or is lost before 2028 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
HURA is a speculative, loss-making biotechnology company rather than an established compounder. Its long-term thesis is on watch: clinical programs are advancing, but recent financial performance is weak and management execution is rated volatile.
The snapshot provides no valuation or market-expectations evidence, so whether HURA is cheap or expensive versus peers cannot be assessed. Its muted recent price reaction does not resolve that gap or change the weak fundamental picture.
Near term, clinical activity may continue to rise: management says key programs are advancing, and research and development spending increased through 2026-Q2. Funding remains a concern, with cash falling to $1.0 million at 2026-Q2 and $5.7 million drawn on the credit facility by 2026-Q3; recent financial-obligation filings add to that concern. The next company update carries meaningful execution risk, and the snapshot flags a high chance of a miss without specifying a forecast.
The multi-year thesis hinges on delivery of clinical milestones, including those expected in the second half of 2026 and in 2027, and progress toward the anticipated orphan drug designations. Near-term, a guidance cut would be a negative, while continued strength among healthcare bellwethers could support the sector backdrop. Continued weakening in the jobs data could weigh on cyclical and healthcare names, though the snapshot gives limited detail on HURA’s specific sensitivity.
Over the next one to three years, HURA’s case rests on clinical progress and access to enough capital to sustain development. The evidence is mixed, with execution progress offset by cash pressure and weak recent performance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in TuHURA Biosciences, Inc.'s published investment case. The stated target is EPS loss narrows from -$0.5 in 2026 to less negative. |
| Broken |
| EPS loss worsens beyond -$0.56 in FY27 |
Diluted EPS: $-0.14 per share FY2026-Q4; GAAP. Published target: EPS loss narrows from -$0.5 in 2026 to less negative. Annual target cannot be compared with a quarterly or TTM observation. Aug 14, 2026-0.14 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Address Nasdaq minimum bid price compliance | A primary condition in TuHURA Biosciences, Inc.'s published investment case. The stated target is Maintain bid price above Nasdaq minimum. | Under Pressure | failure to regain Nasdaq compliance leading to delisting | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.56 → $-0.61 · observed estimates
$0.03B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-25 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-26 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-27 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-28 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-29 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-07-30 | $-0.56 | $0 | 3 / 3 |
| 2026-07-31 | $-0.56 | $0 | 3 / 3 |
| 2026-08-01 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-02 | $-0.56 | $0 | 3 / 3 |
| 2026-08-03 | $-0.56 | $0 | 3 / 3 |
| 2026-08-04 | $-0.56 | $0 | 3 / 3 |
| 2026-08-05 | $-0.56 | $0 | 3 / 3 |
| 2026-08-06 | $-0.56 | $0 | 3 / 3 |
| 2026-08-07 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-08 | $-0.56 | $0 | 3 / 3 |
| 2026-08-09 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-10 | $-0.56 | $0 | 3 / 3 |
| 2026-08-12 | $-0.56 | $0 | 3 / 3 |
| 2026-08-13 | $-0.56 | $0 | 3 / 3 |
| 2026-08-14 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-15 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-16 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-17 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-18 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-19 | $-0.56 | $33,846,000 | 2 / 3 |
| 2026-08-20 | $-0.59 | $33,846,000 | 2 / 3 |
| 2026-08-21 | $-0.59 | $33,846,000 | 3 / 4 |
| 2026-08-22 | $-0.59 | $33,846,000 | 2 / 4 |
| 2026-08-23 | $-0.59 | $33,846,000 | 2 / 4 |
| 2026-08-24 | $-0.59 | $33,846,000 | 2 / 4 |
| 2026-08-25 | $-0.59 | $33,846,000 | 2 / 4 |
| 2026-08-26 | $-0.60 | $16,923,000 | 3 / 4 |
| 2026-08-27 | $-0.60 | $16,923,000 | 3 / 4 |
| 2026-08-28 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-08-29 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-08-30 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-08-31 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-09-01 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-09-02 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-09-03 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-09-04 | $-0.60 | $16,923,000 | 3 / 5 |
| 2026-09-05 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-06 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-07 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-08 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-09 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-10 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-11 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-12 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-13 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-14 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-15 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-16 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-17 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-18 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-19 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-20 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-21 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-22 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-23 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-24 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-25 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-26 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-27 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-28 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-29 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-09-30 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-01 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-02 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-03 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-04 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-05 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-06 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-07 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-08 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-09 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-10 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-11 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-12 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-13 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-14 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-15 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-16 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-17 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-18 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-19 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-20 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-21 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-22 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-23 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-24 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-25 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-26 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-27 | $-0.61 | $22,564,000 | 3 / 5 |
| 2026-10-28 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-10-29 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-10-30 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-10-31 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-11-01 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-11-02 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-11-03 | $-0.61 | $16,923,000 | 3 / 5 |
| 2026-11-04 | $-0.61 | $16,923,000 | 3 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.